COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
  Global AdoptionAdoption
  Submit FeedbackFeedback (DB RCT)80%0.20 [0.01-4.13]death0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)92%0.08 [0.04-0.17]viral+7/17134/66Tau​2 = 0.00; I​2 = 0.0%Early treatment92%0.08 [0.04-0.18]7/30536/20092% improvementCadegiani (DB RCT)91%0.09 [0.05-0.15]death12/294141/296Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment91%0.09 [0.05-0.15]12/294141/29691% improvementAll studies91%0.09 [0.05-0.13]19/599177/49691% improvement3 proxalutamide COVID-19 6/21/21Tau​2 = 0.00; I​2 = 0.0%; Z = 10.74 (p < 0.0001)Lower RiskIncreased Risk
Late Cadegiani et al., Press Conference (Preprint) death, ↓91.4%, p<0.0001 The Proxa-Rescue AndroCoV Trial
Details   RCT 590 hospitalized patients, 294 treated with proxalutamide showing significantly lower mortality and faster recovery.
Early Cadegiani et al., Cureus, doi:10.7759/cureus.13492 (Peer Reviewed) viral+, ↓92.1%, p<0.0001 Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Details   RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery.
Early Goren et al., Frontiers in Medicine, doi:10.3389/fmed.2021.668698 (preprint 12/30/2020) (Peer Reviewed) death, ↓80.0%, p=0.50 Proxalutamide (GT0918) Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Details   RCT 268 male patients in Brazil, 134 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.